Loss of oatp1b3 function causes rotor syndrome: Implications for potential use of inhibitors in cancer

Cancer Biology and Therapy

Volumn 13, Issue 14, 2012, Pages 1374-1375

  Pratt, Elias ^a   Sissung, Tristan M ^a   Figg, William D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; DDI; Inhibition; OATP; Prostate; Rotor syndrome; Therapy

Indexed keywords

CARRIER PROTEIN; OATP1B1 PROTEIN; OATP1B3 PROTEIN; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; CANCER CELL; CANCER GENETICS; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER CELL; NONHUMAN; OVERALL SURVIVAL; PROSTATE CANCER; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; ROTOR SYNDROME; SHORT SURVEY;

ANIMALS; BIOLOGICAL TRANSPORT; HUMANS; HYPERBILIRUBINEMIA, HEREDITARY; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; ORGANIC ANION TRANSPORTERS; ORGANIC ANION TRANSPORTERS, SODIUM-INDEPENDENT;

EID: 84870690048     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.22010     Document Type: Short Survey

References (7)

1. Obaidat A, Roth M, Hagenbuch B. The expression and function of organic anion transporting polypeptides in normal tissues and in cancer. Annu Rev Pharmacol Toxicol 2012; 52:135-51; PMID:21854228; http://dx.doi.org/10.1146/ annurev-pharmtox-010510-100556.
2. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, et al. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 2008; 14:3312-8; PMID:18519758; http://dx.doi.org/10.1158/1078-0432.CCR-07-4118.
3. Sharifi N, Hamada A, Sissung T, Danesi R, Venzon D, Baum C, et al. A polymorphism in a transporter of testosterone is a determinant of androgen independence in prostate cancer. BJU Int 2008; 102:617-21; PMID:18537956; http://dx.doi.org/10.1111/j.1464-410X.2008.07629.x.
4. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, et al. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 2011; 29:2565-73; PMID:21606417; http://dx.doi.org/10.1200/JCO.2010.31.2405.
5. van de Steeg E, Stránecký V, Hartmannová H, Nosková L, Hrebícek M, Wagenaar E, et al. Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. J Clin Invest 2012; 122:519-28; PMID:22232210; http://dx.doi.org/10.1172/JCI59526.
6. Pressler H, Sissung TM, Venzon D, Price DK, Figg WD. Expression of OATP family members in hormone-related cancers: potential markers of progression. PLoS One 2011; 6:e20372; PMID:21625523; http://dx.doi.org/10.1371/journal.pone. 0020372.
7. Sharma P, Butters CJ, Smith V, Elsby R, Surry D. Prediction of the in vivo OATP1B1-mediated drug-drug interaction potential of an investigational drug against a range of statins. Eur J Pharm Sci 2012; 47:244-55; PMID:22538052; http://dx.doi.org/10.1016/j.ejps.2012.04.003.